NeuroOne Medical Technologies Corporation
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-3.6M | $-12.3M | $-11.9M | $-10.0M | $-9.9M | $-13.6M | $-6.8M | $-5.1M |
| Depreciation & Amortization | $261.7K | $246.8K | $199.3K | $118.6K | $80.7K | $47.6K | $27.6K | — |
| Depreciation | $239.4K | $224.5K | $177.0K | $96.3K | $58.4K | $25.3K | $6.3K | — |
| Amortization | $22.3K | $22.3K | $22.3K | $22.3K | $22.3K | $22.3K | $21.2K | $17.6K |
| Stock-Based Compensation | $1.3M | $1.3M | $1.1M | $947.2K | — | — | $324.2K | $76.8K |
| Net Cash from Operating Activities | $-2.8M | $-11.0M | $-12.9M | $-7.5M | $-8.6M | $-3.4M | $-5.4M | $-2.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $81.7K | $120.2K | $384.1K | $275.2K | $67.1K | $122.4K | $58.4K | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-81.7K | $-120.2K | $2.6M | $-3.2M | $-67.1K | $-122.4K | $-123.4K | $-91.7K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $8.0M | $7.3M | $7.4M | $12.0M | $11.5M | $7.3M | $5.8M | $1.7M |
| Net Change in Cash | — | — | — | — | $2.9M | $3.8M | — | — |
| Free Cash Flow | $-2.9M | $-11.1M | $-13.3M | $-7.8M | $-8.7M | $-3.5M | $-5.5M | — |